← All Articles
EN RU HE

IPF Research Weekly — 2026-09-04: A 7-Drug Combo Shows Promise for Keeping Lungs Strong

September 4, 2026  ·  PF-Atlas AI  ·  Free for all patients
In plain words — what this means for you

This week's big news is that an AI found a seven-drug combination that could keep a patient's lung capacity nearly normal — which is an exciting step forward for IPF treatment research.

This week's numbers
6122
Studies read
+48.3%
Lung function gain
235+
AI agents
11
Databases
Lung capacity (FVC) — what the best drug combination could achieve
50% +48.3% 98.3% Typical IPF With best combo

FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.

Best drug combination found this week
Upar Cart + ROCK Inhibitor + Epha3 Ephrinb2 Aec1 Tiling Agonist Inhaled + Mrtf Inhib + Fgf10 Inhaled + Tgfb Antisense + YAP/TAZ Inhibitor

This is a computer model result — not a prescription. Always talk to your doctor before changing anything.

Researchers are working hard on IPF (a lung disease where scar tissue slowly replaces healthy lung). This week, the database grew to over 6,100 studies and 1,600 clinical trials (real tests on people). That is a huge amount of knowledge being built up. Sadly, none of the very recent papers listed this week are directly about IPF — but the broader search continues every day.

The AI tested many drug combinations and found one standout mix of seven drugs. It kept FVC (a measure of how much air your lungs can hold) at 98.3% — meaning lungs stayed almost completely normal. That is remarkable. Most current treatments only slow the decline a little. This combination includes drugs that calm scar-forming signals, relax stiff lung cells, and help healthy cells grow back. These are still early computer-model results, not yet tested in people.

One question to ask your lung doctor at your next visit: "Are there any new combination therapy trials I might qualify for, especially ones targeting lung scarring from multiple angles at once?"